It looks like Unilever double downed and has bet big on home care market. Illuminage Beauty will have cosmetic products from Unilever, light skin products from Syneron, and laser treatment products from Cynosure, all funded by Unilever and its venture arm. If it works they can fold it in and if it does just OK, they can spin it out. I hope CYNO stays involved even though they have been piggy backed since their focus is on professional cosmetic medical practioners and clinics. Home care through Illuminag would be gravy for CYNO even though Syneron has more upside. None of my valuation models that project $40 for CYNO's stock included anything whasoever for home care where proprietary intellectual assets carry less leverage. I still believe that, over the next quarter, as acquisition expenses fade away and GAAP EPS approach non-GAAP EPS, EPS will jump towards $1.50 per share and the stock will progress to $35-$45.